AZD1480 CAS: 935666-88-9
MF: C14H14ClFN8
MW: 348.77
An inhibitor of JAK2.

AZD1480 (CAS 935666-88-9)

AZD1480 | CAS 935666-88-9 is rated 5.0 out of 5 by 2.
  • y_2021, m_10, d_18, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.19
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_2
  • loc_en_US, sid_364735, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 134ms
  • REVIEWS, PRODUCT
loading
5
2
4
0
3
0
2
0
1
0
Alternate Names: (S)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
Application: AZD1480 is an inhibitor of JAK2
CAS Number: 935666-88-9
Purity: ≥98%
Molecular Weight: 348.77
Molecular Formula: C14H14ClFN8
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits
loading

AZD1480 is a novel ATP-competitive inhibitor of JAK2 (IC50 = 0.26 nM).

Physical State :
Solid
Solubility :
Soluble in DMSO (70 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).
Storage :
Store at -20° C
Melting Point :
213.39° C (Predicted)
Boiling Point :
~575.2° C at 760 mmHg (Predicted)
Density :
~1.5 g/cm3 (Predicted)
Refractive Index :
n20D 1.70 (Predicted)
IC50 :
JAK2: IC50 = 0.26 nM; Trk A: IC50 = 3 nM (human); Stat3: IC50 = 23 nM (human); Stat5a: IC50 = 25 nM (human); JAK3: IC50 = 1.36 µM (human)
pK Values :
pKa: 13.73 (Predicted), pKb: 4.37 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
MDL Number :
MFCD16038904
SMILES :
CC1=CC(=NN1)NC2=NC(=NC=C2Cl)N[[email protected]@H](C)C3=NC=C(C=N3)F

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

AZD1480 (CAS 935666-88-9)  Product Citations

See how others have used AZD1480 (CAS 935666-88-9). Click on the entry to view the PubMed entry .

Citations 1 to 8 of 8 total

PMID: # 30981183  Hwang, ST.|Kim, C.|Lee, JH.|Chinnathambi, A.|Alharbi, SA.|Shair, OHM.|Sethi, G.|Ahn, KS.| et al. 2019. Phytomedicine. 59: 152907.

PMID: # 28676702  Bridgewater, RE.|Streuli, CH.|Caswell, PT.| et al. 2017. Sci Rep. 7: 4572.

PMID: # 27199222  Thorn, M. et al. 2016. Cancer gene therapy. 188-198.

PMID: # 33194044  Am J Transl Res. 6464-6477.

PMID: # 30963819  Thyroid. 700-713.

PMID: # 32910932  J. Allergy Clin. Immunol.

PMID: # 28659618  Leukemia. 92-101.

PMID: # 31680865  Front Cell Neurosci. 13: 446.

Citations 1 to 8 of 8 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 98ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from It worked well in our experiments It worked well in our experiments, no complaints.
Date published: 2015-06-05
Rated 5 out of 5 by from Liu X; et al Liu X; et al. (PubMed ID: 25954974) determined that AZD1480, an AK2 inhibitor, blocked the effect of COX-2/PGE2 on expression of MMP-2/-9. -SCBT Publication Review
Date published: 2015-06-05
  • y_2021, m_10, d_18, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.19
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_2
  • loc_en_US, sid_364735, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 15ms
  • REVIEWS, PRODUCT